David A. Siegel Cara Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 866,300 shares of CARA stock, worth $259,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares

866,300

Previous 861,600 0.55%

Holding current value

$259,890

Previous $224,000 19.64%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.26 - $0.38 $1,222 - $1,786	4,700 Added 0.55%	866,300 $268,000
Q2 2024 Aug 14, 2024	BUY	$0.24 - $0.92 $48,408 - $185,564	201,700 Added 30.57%	861,600 $224,000
Q1 2024 May 15, 2024	BUY	$0.52 - $1.05 $75,764 - $152,985	145,700 Added 28.34%	659,900 $600,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.65 $226,080 - $621,720	376,800 Added 274.24%	514,200 $380,000
Q3 2023 Nov 14, 2023	BUY	$1.67 - $3.33 $15,364 - $30,636	9,200 Added 7.18%	137,400 $230,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $289,509 - $505,362	102,300 Added 394.98%	128,200 $362,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $126,650 - $317,793	25,900 New	25,900 $127,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $13.84 $5,215 - $9,688	-700 Reduced 3.95%	17,000 $155,000
Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $175,938 - $223,905	17,700 New	17,700 $215,000
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $816,519 - $1.24 Million	-68,100 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $2.28 Million - $3.17 Million	-197,400 Reduced 74.35%	68,100 $1.05 Million
Q2 2021 Aug 16, 2021	SELL	$12.38 - $29.19 $1.39 Million - $3.28 Million	-112,200 Reduced 29.71%	265,500 $3.79 Million
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $1.67 Million - $2.4 Million	110,600 Added 41.41%	377,700 $8.2 Million
Q4 2020 Feb 16, 2021	BUY	$12.72 - $16.16 $376,512 - $478,336	29,600 Added 12.46%	267,100 $4.04 Million
Q3 2020 Nov 16, 2020	BUY	$12.34 - $17.92 $1.7 Million - $2.47 Million	138,100 Added 138.93%	237,500 $3.02 Million
Q2 2020 Aug 14, 2020	BUY	$12.39 - $17.33 $952,791 - $1.33 Million	76,900 Added 341.78%	99,400 $1.7 Million
Q1 2020 May 15, 2020	BUY	$9.12 - $17.78 $13,679 - $26,670	1,500 Added 7.14%	22,500 $297,000
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $111,159 - $179,262	6,900 Added 48.94%	21,000 $338,000
Q3 2019 Nov 14, 2019	BUY	$18.28 - $26.91 $257,748 - $379,431	14,100 New	14,100 $258,000
Q2 2019 Aug 14, 2019	SELL	$17.68 - $21.57 $659,464 - $804,561	-37,300 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$14.41 - $19.64 $33,143 - $45,172	-2,300 Reduced 5.81%	37,300 $732,000
Q4 2018 Feb 14, 2019	BUY	$12.45 - $23.47 $257,714 - $485,829	20,700 Added 109.52%	39,600 $515,000
Q3 2018 Nov 14, 2018	BUY	$17.57 - $23.95 $332,073 - $452,655	18,900 New	18,900 $453,000
Q1 2018 May 15, 2018	SELL	$11.77 - $16.08 $190,674 - $260,495	-16,200 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$11.86 - $14.08 $10,674 - $12,672	-900 Reduced 5.26%	16,200 $198,000
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $215,460 - $279,414	17,100	17,100 $234,000

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.1M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account